Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (RACATREX)
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Therapy.
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Listed as NCT01528163, this PHASE2 trial focuses on Squamous Cell Carcinoma of the Head and Neck and remains completed. Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baudour, Belgium , Brussels, Belgium , Charleroi, Belgium , Ghent, Belgium , Haine-Saint-Paul, Belgium , La Louvière, Belgium , Liège, Belgium , Luxembourg, Luxembourg , Mons, Belgium , Montigny-le-Tilleul, Belgium and 4 more locations